Stock Events

Calithera Biosciences 

$0.01
17
+$0+0% Friday 17:33

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
97,450
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

29MarExpected
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
-5.6
-4.26
-2.93
-1.59
Expected EPS
-1.68
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CALA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap13.28B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including cancer treatments that directly compete with Calithera's oncology portfolio.
Exelixis
EXEL
Mkt Cap6.37B
Exelixis, Inc. is involved in the development and commercialization of cancer treatments, competing in the oncology space with drugs that may target similar pathways as Calithera's products.
Array Technologies
ARRY
Mkt Cap2.04B
Array BioPharma Inc. specializes in the development of drugs for the treatment of cancer, including targeted small molecule drugs designed to treat patients with specific mutations, competing with Calithera's approach to cancer therapy.
Agios Pharmaceuticals
AGIO
Mkt Cap2.7B
Agios Pharmaceuticals, Inc. focuses on cellular metabolism and rare genetic diseases, including cancer metabolism, which competes with Calithera's research into cancer cell metabolism.
BeiGene
BGNE
Mkt Cap14.96B
BeiGene, Ltd. is a global biotechnology company that develops molecularly targeted and immuno-oncology drugs for cancer patients, competing in the same therapeutic areas as Calithera.
Novartis
NVS
Mkt Cap230.67B
Novartis AG, through its extensive portfolio of oncology drugs, competes across a broad range of cancer types, potentially including those targeted by Calithera's treatments.
Puma Biotechnology
PBYI
Mkt Cap170.04M
Puma Biotechnology, Inc. focuses on the development and commercialization of a targeted therapy for breast cancer, competing in the oncology market where Calithera is also seeking to establish a presence.
Bluebird bio
BLUE
Mkt Cap98.95M
bluebird bio, Inc. focuses on gene therapies for severe genetic diseases and cancer, competing with Calithera in the innovative treatment space, particularly in oncology.

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Show more...
CEO
Susan Molineaux
Employees
8
Country
US
ISIN
US13089P5070
WKN
000A3DMJB

Listings